Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dasotraline in Adults with ADHD
NCT02160262Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dasotraline in attention deficit hyperactivity disorder (ADHD), sponsored by Sumitomo Pharma America. Started Jun 2014; status: completed.
02
Drugs
dasotraline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02160262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02160262.